Tag: evaluating
Nanobiotix: randomization of the 1st patient in the USA in the pivotal global Phase 3 trial evaluating the radioenhancer NBTXR3 in head and neck cancer
By Jean-Baptiste André Published on 27/12/2022 at 08:41 Photo credit © Nanobiotix (Boursier.com)…
First clinical trial evaluating glenzocimab in myocardial infarction – 2022-11-22 at 18:00
To receive all of Acticor Biotech’s financial information in real time, send a request by email to [email protected] Thanks to a partnership between the University of Birmingham and Acticor Biotech,…
NANOBIOTIX ESTABLISHES RECOMMENDED DOSE FOR REGISTRATION STUDY EVALUATING NBTXR3 + ANTI-PD-1 COMBINATION IN PATIENTS WITH METASTATIC HEAD AND NECK CANCER AND IMMUNOTHERAPY RESISTANT – 09/21/2022 at 22 :20
• Recommended dose for phase 2 of the dose escalation part of study 1100, established at 33% of the tumor volume (GTV) in the three cohorts of the study. •…
THERANEXUS: Theranexus and the BBDF foundation finalize the recruitment of the phase I/II study evaluating Batten-1 in Batten disease – 09/08/2022 at 18:00
Lyon, France – Austin, Texas, United States – September 8, 2022 – 6:00 p.m. CEST – Theranexus, an innovative biopharmaceutical company in the treatment of neurological diseases and a pioneer…
NANOBIOTIX AND LIANBIO ANNOUNCE THE RECRUITMENT OF THE FIRST PATIENT IN ASIA FOR THE NANORAY-312 PHASE 3 TRIAL, EVALUATING NBTXR3 IN THE MANAGEMENT OF HEAD AND NECK CANCERS – 09/07/2022 at 22:20
• The implementation of the pivotal Phase 3 trial of Nanobiotix in the treatment of head and neck cancers is progressing as planned: LianBio, partner of Nanobiotix, recruited the first…
IT security audit: the vital importance of evaluating your information system!
The IT security audit is one of the first steps to take to identify your security breaches and thus protect the daily lives of your employees, your data and your…
NOXXON Presents Key Data from Phase 1/2 GLORIA Study Evaluating NOX-A12 in Glioblastoma at ASCO 2022 Annual Meeting – 06/05/2022 at 15:00
To receive all the news in real time from NOXXON, please contact [email protected] Berlin, Germany, June 5, 2022, 3:00 p.m. CEST – NOXXON Pharma NV (Euronext Growth Paris: ALNOX), a…
MaaT Pharma confirms the positive results of the CIMON Phase 1b study evaluating MaaT033 in patients with blood cancer – 06/02/2022 at 18:11
Lyon, France, June 2, 2022 – 6:00 p.m. CEST – MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotechnology company pioneering the development of Microbiome Ecosystem TherapiesTM (MET)…
MaaT Pharma announces the initiation of an investigator-sponsored Phase 2a clinical trial evaluating MaaT013 in combination with immunotherapies for patients with melanoma – 04/07/2022 at 18:10
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French late-stage biotechnology company, a pioneer in the development of drugs to restore the gut microbiota to improve the survival of cancer…
ERYTECH announces the publication of positive results from the phase 2 trial evaluating eryaspase in hypersensitive ALL in the British Journal of Haematology – 04/06/2022 at 22:05
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected] Lyon (France), and Cambridge, MA…
MaaT Pharma announces the treatment of a first patient in the Phase 3 “ARES” clinical study evaluating MaaT013 in the treatment of acute graft versus host disease – 03/28/2022 at 18:15
Pivotal Phase 3 Clinical Trial Investigates Efficacy of MaaT Pharma’s Most Advanced Microbiome Ecosystem Therapy, MaaT013, as a Third-Line Treatment in Patients with Acute Graft-vs-Host Disease with Gastrointestinal Component -intestinal…
Sanofi provides an update on the phase II study evaluating amcenestrant in the treatment of advanced or metastatic ER+/HER2- breast cancer – 03/14/2022 at 07:00
Sanofi takes stock of the phase II study evaluating the amcenestrant in the treatment of breast cancer ER+/HER2- at an advanced or metastatic stage The AMEERA-3 trial failed to meet…